

**T1508. Amyloid Imaging with Florbetapir-PET
Correlates with Cognitive Performance in
Non-Demented Oldest-Old**

Maria M. Corrada, Dana E. Greenia, Chris M. Clark, Carrie B. Peltz, Mark A. Mintun, Michael J. Pontecorvo, Abhinay D. Joshi and Claudia H. Kawas; Irvine, CA; Philadelphia, PA and St. Louis, MI

We examined the association between amyloid imaging with florbetapir F18 positron emission tomography (PET) and cognitive performance in non-demented oldest-old.

Thirteen non-demented oldest-old subjects received a florbetapir-PET scan within 3 months of neuropsychological testing, which included the Modified Mini-Mental State Exam (3MS), California Verbal Learning Test (CVLT) 10-minute delay, Boston Naming Test, and Trails A and B. Scans were analyzed with a semiautomated quantitative analysis of the cortical to cerebellar signal ratio (SUVr) on the average of 6 cortical brain regions (frontal, temporal, parietal, anterior and posterior cingulate, and precuneus).

Participants were 9 women and 4 men with an average age of 94.2 years (range:90–99). Eight participants were diagnosed as cognitively normal and 5 had cognitive impairment but did not meet dementia criteria. CVLT scores correlated significantly with the average SUVr (Pearson corr = -0.64 , $p = 0.03$) and 3MS scores trended towards a significant correlation with the average SUVr (Pearson corr = -0.54 , $p = 0.07$).

This preliminary study suggests that greater amyloid burden is associated with poorer cognition, especially memory, in non-demented oldest-old participants. Amyloid imaging may identify oldest-old individuals at increased risk of developing Alzheimer's disease.

Study supported by: NIH grant RO1AG21055 and Avid Radiopharmaceuticals, Inc.

Dr. Kawas and Ms. Grenia received a grant from Avid Radiopharmaceuticals (awarded to UCI) for their participation in this study. Dr. Clark, Dr. Mintun, Dr. Pontecorvo, and Mr. Joshi are employees of Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.